Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults

Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults Despite the increasing recognition of attention-deficit hyperactivity disorder (ADHD) in adults, there are few controlled trials demonstrating the effectiveness of pharmacological treatments, particularly with nonstimulants. One controlled trial found bupropion SR more effective than placebo in the treatment of ADHD adults. We conducted a controlled study to contrast the effectiveness of bupropion SR and methylphenidate to placebo in ADHD adults. A randomized, double-blind, parallel design was used in this study. Following a 7-day placebo lead-in, 30 ADHD (DSM-IV) subjects (18–60 years old) were randomized to bupropion, methylphenidate, or placebo for 7 weeks. Methylphenidate was titrated over 1 week to a maximum dose of 0.9 mg/kg/d divided into 3 doses while bupropion was titrated over 2 weeks to a maximum dose of 200 mg A.M. and 100 mg P.M. Response rates based on Clinical Global Impression improvement ratings in patients receiving bupropion, methylphenidate, and placebo were 64, 50, and 27%, respectively. The difference in response rates between active treatment and placebo was not statistically significant (p = 0.14). Neuropsychological testing demonstrated trends favoring drug treatment on measures of immediate recall and verbal fluency. While bupropion SR may be a viable clinical alternative for adults with ADHD, further investigation is needed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Bupropion SR vs. Methylphenidate vs. Placebo for Attention Deficit Hyperactivity Disorder in Adults

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/bupropion-sr-vs-methylphenidate-vs-placebo-for-attention-deficit-wePepmd0lo
Publisher
Springer Journals
Copyright
Copyright © 2001 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1012239823148
Publisher site
See Article on Publisher Site

Abstract

Despite the increasing recognition of attention-deficit hyperactivity disorder (ADHD) in adults, there are few controlled trials demonstrating the effectiveness of pharmacological treatments, particularly with nonstimulants. One controlled trial found bupropion SR more effective than placebo in the treatment of ADHD adults. We conducted a controlled study to contrast the effectiveness of bupropion SR and methylphenidate to placebo in ADHD adults. A randomized, double-blind, parallel design was used in this study. Following a 7-day placebo lead-in, 30 ADHD (DSM-IV) subjects (18–60 years old) were randomized to bupropion, methylphenidate, or placebo for 7 weeks. Methylphenidate was titrated over 1 week to a maximum dose of 0.9 mg/kg/d divided into 3 doses while bupropion was titrated over 2 weeks to a maximum dose of 200 mg A.M. and 100 mg P.M. Response rates based on Clinical Global Impression improvement ratings in patients receiving bupropion, methylphenidate, and placebo were 64, 50, and 27%, respectively. The difference in response rates between active treatment and placebo was not statistically significant (p = 0.14). Neuropsychological testing demonstrated trends favoring drug treatment on measures of immediate recall and verbal fluency. While bupropion SR may be a viable clinical alternative for adults with ADHD, further investigation is needed.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 19, 2004

References

  • Diagnostic and Statistical Manual of Mental Disorders
  • Attention deficit hyperactivity disorder in adults
    Bellak, L; Black, RB
  • Psychiatric status of hyperactives as adults: A controlled prospective 15–year follow-up of 63 hyperactive children
    Weiss, G; Hechtman, L; Milroy, T; Perlman, T
  • Diagnosis and treatment of minimal brain dysfunction in adults
    Wood, DR; Reimherr, FW; Wender, PH
  • Attention deficit disorder ('minimal brain dysfunction') in adults
    Wender, PH; Reimherr, FW; Wood, D
  • Methylphenidate effects on symptoms of attention-deficit disorder in adults
    Mattes, JA; Boswell, L; Oliver, H
  • A controlled study of methylphenidate in the treatment of attention-deficit disorder, residual type, in adults
    Wender, PH; Reimherr, FW; Wood, D; Ward, M
  • Attention deficit disorder in adults
    Gualtieri, CR; Ondrusek, MG; Finley, C
  • A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder
    Spencer, T; Wilens, T; Biederman, J; Faraone, SV; Ablon, JS; Lapey, K
  • Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder
    Wilens, TE; Biederman, J; Prince, J; Spencer, TJ; Faraone, SV; Warburton, R; Schleifer, D; Harding, M; Linehan, C; Geller, D
  • Bupropion treatment of attention-deficit hyperactivity disorder in adults
    Wender, PH; Reimherr, FW
  • Structured Clinical Interview for DSM-III-R-Non-Patient Edition (SCID-NP, Version 1.0)
    Spitzer, RL; Williams, JB; Gibbon, M; First, MB
  • Seizures and bupropion: A review
    Davidson, J
  • Treatment of bulimia with bupropion: A multicenter controlled trial
    Horne, RL; Ferguson, JM; Pope, HG; Hudson, JI; Lineberry, CG; Ascher, J; Cato, A
  • Attention-deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment
    Barkley, RA
  • Development of a rating scale for primary depressive illness
    Hamilton, M
  • The assessment of anxiety states by rating
    Hamilton, M